复方丹参滴丸在41例中晚期胰腺癌化疗中的应用

[目的]对比分析复方丹参滴丸联合化疗和单纯化疗对中晚期胰腺癌疗效及生存质量的影响.[方法]81例中晚期胰腺癌患者随机分为A、B两组,A组(41例)采用复方丹参滴丸加健择 顺铂(GP方案)治疗,B组(40例)采用单纯GP方案化疗,对其疗效、生存质量及不良反应进行评价.[结果] A、B两组的有效率(CR PR)分别为46.3%和35.0%(P＞0.05),A、B两组的临床获益率(CR PR SD)分别为73.2%和50.0%(P＜0.05),A组治疗后T淋巴细胞亚群中CD4/CD8比值有明显提高(P＜0.01),而B组治疗后T淋巴细胞亚群中的CD4/CD8比值有明显降低(P＜O.01),生存质量A组高于B组(P＜0.05),恶心呕吐和白细胞减少B组高于A组(P＜0.05).[结论]复方丹参滴丸与化疗同时应用治疗胰腺癌能提高患者的治疗临床获益率、改善生存质量、减轻化疗不良反应.

Effect of Composite Salviae Dropping Pill Combined with Chemotherapy in 41 Cases with Pancreatic Carcinoma

To investigate the response and impact of Composite Salviae Dropping Pill (CSDP) combined with chemotherapy on guality of life (QOL) in advanced pancreatic carcinoma. Eighty-one cases with advanced pancreatic carcinoma were randomly divided into 2 groups: group A (41 cases), received gemcitabine and cisplatin combined chemotherapy (GP regimen), group B (40 cases), received GP regimen alone. The response, QOL, toxicity were evaluated. The objective response rate (CR+PR) was 46.3% in group A, compared to 35.0% in group B(P<0.05). The clinical benefit response rate (CR+PR+SD) was 73.2% in group A, compared to 50.0% in group B (P<0.05). The level of CD4/CD8 was significantly increased in group A, the level of CD4/CD8 was significantly decreased in group B. QOL in group A was higher than that in group B (P<0.05), nausea, vomiting, leukopenia in group B were more serious than those in group A (P<0.05). [Conclusion] Chemotherapy combined with CSDP reveals satisfactory clinical benefit, decreasing side effects of chemotherapy, improving QOL in patients with pancreatic carcinoma.